1. PIKFYVE inhibition has been found to mitigate disease in models of diverse forms of ALS, including C9ORF72, TARDBP, FUS, and sporadic.
2. PIKFYVE inhibition activates an unconventional protein clearance mechanism involving exocytosis of aggregation-prone proteins.
3. Reducing PIKFYVE activity ameliorates ALS pathology and extends survival of animal models and patient-derived motor neurons representing diverse forms of ALS.
The article is generally reliable and trustworthy as it provides evidence for its claims through the use of scientific studies and experiments. The article also provides a comprehensive overview of the research conducted on PIKFYVE inhibition in relation to ALS, which is supported by evidence from multiple sources such as iPSC and animal models. Furthermore, the article does not appear to be biased or one-sided as it presents both sides equally and does not make any unsupported claims or omit any points of consideration. Additionally, the article does not contain any promotional content or partiality towards any particular point of view. Finally, the article does note possible risks associated with PIKFYVE inhibition such as potential side effects or long-term consequences that may arise from chronic reduction in PIKFYVE activity.